Germline testing in lung cancer: evidence of enrichment without a standardized selection strategy - a systematic review [0.03%]
肺癌患者胚系基因检测的系统评价：亚组人群富集度增加但缺乏标准化选择策略
Fabrizio Citarella,Roberto Ferrara,Massimo Di Maio et al.
Fabrizio Citarella et al.
Background: Germline testing (GT) is increasingly integrated into oncology practice, yet its role in lung cancer (LC) remains undefined. While germline predisposition has clinical implications in several malignancies, LC ...
Adjuvant chemotherapy intensity and prognosis in completely resected high-grade neuroendocrine lung carcinoma: a post hoc analysis of JCOG1205/1206 [0.03%]
辅助化疗强度与完全切除的高分级肺神经内分泌癌预后的关联：JCOG1205/1206试验的事后分析
Tetsuya Isaka,Hirotsugu Kenmotsu,Masashi Wakabayashi et al.
Tetsuya Isaka et al.
Introduction: We aimed to clarify the prognostic impact of adjuvant chemotherapy intensity in patients with high-grade neuroendocrine carcinoma (HGNEC) of the lung using a post hoc analysis of the phase III JCOG1205/1206 ...
SMARCA4-mutant CUP-lung: from a diagnostic shortcut to biological and therapeutic reflections [0.03%]
SMARCA4突变型CUP-肺：从诊断捷径到生物学和治疗的思考
Huang Dongqiao,Shi Mengting
Huang Dongqiao
Nanoparticle-based drug delivery for precision lung cancer therapy: Tumor microenvironment modulation and theranostic applications [0.03%]
基于纳米颗粒的药物输送用于精准肺癌治疗：肿瘤微环境调节和诊疗应用
Ramaraj Rajesh Kumar,Israel Vmv Enoch
Ramaraj Rajesh Kumar
Lung cancer still remains a serious global public health problem, with high mortality rates mainly due to late diagnosis, tumor metastasis and the intrinsic constraints of classical treatment strategies (chemotherapy/radiotherapy). Systemic...
ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model [0.03%]
ULK1是延缓EGFR突变非小细胞肺癌模型耐药的靶点
Ayako Morita,Kammei Rai,Tadahiro Kuribayashi et al.
Ayako Morita et al.
Background: The presence of drug-tolerant persister (DTP) cells reduces the effectiveness of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in EGFR-mutated non-small cell lung cancer (NSCLC). Al...
Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy [0.03%]
EGFR-TKI长期治疗后携带复合型EGFR G719X/S768I突变的NSCLC中克隆演化及新发BRAF V600E变异导致耐药
Camilla Hviid,Linea C Melchior,Siv M S Berger et al.
Camilla Hviid et al.
Background: Uncommon EGFR-mutations represent a heterogeneous subgroup of EGFR-mutant NSCLC with variable TKI sensitivity and limited evidence to guide treatment. Compound uncommon variants such as G719X/S768I are particu...
Corrigendum to "European experience on oncological outcomes of patients with early stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" [Lung Cancer J. 217 (2026) 109410] [0.03%]
关于“早期非小细胞肺癌且有既往癌症患者在肺叶切除或肺段切除后欧洲地区肿瘤学结果经验”的勘误( Lung Cancer 杂志第 217 卷(2026年) 109410 页面)
Lukadi Joseph Lula,Rita Costa,Lin Huang et al.
Lukadi Joseph Lula et al.
Published Erratum
Lung cancer (Amsterdam, Netherlands). 2026 Jul 1:109511. DOI:10.1016/j.lungcan.2026.109511 2026
Proportion of lung cancer patients eligible for screening in France: Data from the KBP-2020-CPHG study [0.03%]
法国肺癌筛查符合标准患者的占比：KBP-2020-CPHG研究的数据分析
Sebastien Couraud,Emmanuel Grolleau,Jacques Letreut et al.
Sebastien Couraud et al.
Background: Lung cancer remains the leading cause of cancer-related mortality worldwide. Screening with low-dose CT reduces lung cancer mortality. France implemented a pilot lung cancer screening program in may 2026 targe...
Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer [0.03%]
25946例非小细胞肺癌患者中NTRK融合的发生率和临床特征
Teodora Radonic,Sepehr Rahmani-Khajouei,Urania Dafni et al.
Teodora Radonic et al.
Background: Functional NTRK1-2-3 fusions are rare, tumor-agnostic, targetable alterations. Accurate detection is essential to ensure optimal treatment. We investigated the prevalence of NTRK fusions in two cohorts of pati...
Prognostic impact of the 9th vs 8th TNM classification in small-cell lung cancer. a population-based study [0.03%]
基于人群的肺癌分型对小细胞肺癌预后的预测价值：第9版与第8版TNM分期系统的比较研究
A Dan,S Tendler,G Wagenius et al.
A Dan et al.
Background: Small cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis. The traditional limited and extensive-stage classification does not adequately capture disease heterogeneity. The tumor-node-metas...